Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insurance
Authors:
- 4 December 2025
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (3) , 317-323
Abstract
Background: Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) are preventive options for women with hereditary breast and ovarian cancer (HBOC). The Japanese national medical insurance began covering RRM and RRSO for patients with HBOC in April 2020. Methods: We retrospectively analyzed 59 individuals with pathogenic germline variants (PGVs) from 55 families diagnosed with HBOC between 2010 and 2024 to assess the prevalence of RRM and RRSO after April 2020. Results: The median age at diagnosis was 50 years. Ten individuals (16.9%) were diagnosed before April 2020, whereas 49 (83.1%) were diagnosed afterward. PGVs included BRCA1 (28 individuals) and BRCA2 (31 individuals). The most common cancer was breast cancer (74.6%), followed by ovarian (13.6%), and pancreatic cancer (3.3%); 15.3% had no cancer history. RRM was performed in 19 of 41 individuals (46.3%), with the highest rate observed among BRCA1 PGV individuals (55.0%). RRSO was conducted in 30 of 41 individuals (73.1%), with higher rates among BRCA1 and BRCA2 PGV individuals. None of the individuals without a history of breast and/or ovarian cancer underwent these procedures. The median age was 50 for RRM and 49 for RRSO. Most surgeries (64.7% for RRM and 76.0% for RRSO) occurred within a year of genetic testing. Multivariate analysis showed that breast cancer history was strongly associated with RRM. Conclusions: National insurance coverage has enhanced access to genetic testing and preventive surgeries, with 46.3% and 73.1% undergoing RRM and RRSO, respectively. However, individuals without a cancer history remain underrepresented.Keywords
This publication has 36 references indexed in Scilit:
- MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJAMA Oncology, 2024
- Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in JapanInternational Journal of Clinical Oncology, 2019
- Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutationsCochrane Database of Systematic Reviews, 2018
- Risk-reducing mastectomy for the prevention of primary breast cancerCochrane Database of Systematic Reviews, 2018
- Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutationsFamilial Cancer, 2017
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriersBreast Cancer Research and Treatment, 2014
- Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysisInternational Journal of Cancer, 2014
- Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancerBreast Cancer Research and Treatment, 2013
- Women's Decision Making about Risk‐Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic ReviewJournal of Genetic Counseling, 2009